- Clinical Benefit Associated with Participation in Modern Phase I Oncology Studies
- ASCO 2018: Large Study of DNA Mismatch Repair Genes Determines Mutation Frequency in Several Types of Cancer
- FDA Approves Pembrolizumab for Treatment of Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma
- FDA Approves Bevacizumab in Combination with Chemotherapy for Ovarian Cancer
- FDA Approves Pembrolizumab for Advanced Cervical Cancer with Disease Progression During or After Chemotherapy
- 20 Years of Excellence in Gastrointestinal Research and Practice [WCGI Media Alert]
Leading the Debate on the Advances in Healthcare